Document is current
Any future updates will be listed below
-
Authors
Thurman, Angela John https://orcid.org/0000-0003-4220-7897
Nunnally, Amanda Dimachkie
Nguyen, Vivian
Berry-Kravis, Elizabeth
Sterling, Audra
Edgin, Jamie
Hamilton, Debra
Aschkenasy, Jeannie
Abbeduto, Leonard
-
Funding
Funding for this research was provided by:
Eunice Kennedy Shriver National Institute of Child Health and Human Development (R01HD074346, P50HD103526)
National Center for Advancing Translational Sciences (UL1TR001860)
- License Information
-
More Information
Article History
Accepted: 20 August 2024
First Online: 9 September 2024
Declarations
:
: The larger project from which the current data were taken was funded by the National Institute of Health and the Simons Foundation. The funders had no role in the design of the study; in the collection, analysis, or interpretation of data; in the writing of the manuscript, or in the decision to publish the results. Elizabeth Berry-Kravis has received funding from Acadia, Alcobra, AMO, Asuragen, Avexis, Biogen, BioMarin, Cydan, Engrail, Erydel, Fulcrum, GeneTx, GW, Healx, Ionis, Jaguar, Kisbee, Lumos, Marinus, Mazhi, Moment Biosciences, Neuren, Neurogene, Neurotrope, Novartis, Orphazyme/Kempharm/Zevra, Ovid, PTC Therapeutics, Retrophin, Roche, Seaside Therapeutics, Taysha, Tetra, Ultragenyx, Yamo, Zynerba, and Vtesse/Sucampo/Mallinckrodt Pharmaceuticals, to consult on trial design or run clinical or lab validation trials in genetic neurodevelopmental or neurodegenerative disorders, all of which is directed to RUMC in support of rare disease programs; Dr Berry-Kravis receives no personal funds and RUMC has no relevant financial interest in any of the commercial entities listed. Study authors declare no conflicts of interest.
